Login / Signup

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines.

Filipe Colaço MarizNoemi BenderDevasena AnantharamanPartha BasuNeerja BhatlaMadhavan Radhakrisna PillaiPriya R PrabhuRengaswamy SankaranarayananTiina ErikssonMichael PawlitaKristina PragerPeter SehrTim WaterboerMartin MüllerMatti Lehtinen
Published in: NPJ vaccines (2020)
We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine. The correlation of bivalent vaccine-induced HPV45 ab-levels with HPV16/18 ab-levels was stronger than that of corresponding quadrivalent vaccine-induced ab-levels, suggesting a qualitatively different cross-reactive response. Our findings on the comparison of the immunogenicity of two HPV vaccine tested in two different populations indicate that further head-to-head studies are warranted.
Keyphrases
  • high grade
  • dengue virus
  • mental health
  • oxidative stress
  • single cell